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Abstract
Voltage-gated calcium channels (VGCCs) manage the electrical signaling of cells by 
allowing the selective-diffusion of calcium ions in response to the changes in the cellular 
membrane potential. Among the different VGCCs, the long-lasting or the L-type calcium 
channels (LTCCs) are prevalently expressed in a variety of cells, such as skeletal muscle, 
ventricular myocytes, smooth muscles and dendritic cells and forms the largest family of 
the VGCCs. Their wide expression pattern and significant role in diverse cellular events, 
including neurotransmission, cell cycle, muscular contraction, cardiac action potential 
and gene expression, has made these channels the major targets for drug development. In 
this book chapter, we aim to provide a comprehensive overview of the different VGCCs 
and focus on the sequence-structure–function properties of the LTCCs. Our chapter will 
summarize and review the various experimental and computational analyses performed 
on the structures of the LTCCs and their implications in drug discovery applications.
Keywords: CaV1.2, L-type calcium channel, ion channel blocker, high-voltage 
activation, low-voltage activation
1. Introduction
1.1. L-type calcium channel introduction
The voltage-gated calcium channels (VGCCs/CaVs), are transmembrane ion channel proteins 
that selectively conduct calcium ions through the cell membrane in response to the membrane 
potential during depolarization. In 1953, Paul Fatt and Bernard Katz discovered the existence 
of calcium-conducting ion channels in the crustacean muscle [1]. Following the initial discov-
ery of the presence of calcium conducting ion channels in the crustacean muscle cells, several 
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reports confirmed the presence of these channels in various mammalian cell types including, 
skeletal, cardiac muscles and all excitable cells. These calcium channels were firstly classified 
into two types based on their activation voltage and conductance, the high-voltage-activated 
(HVA) and the low-voltage-activated (LVA) calcium channels [2]. The HVA and LVA channels 
were reported to have distinct gating properties and pharmacological profiles [2, 3]. Hess 
et al. [4] found that the HVA channels are sensitive to 1,4-dihydropyridine (DHPs) antago-
nists and DHPs agonists help in stabilizing the HVA channels in the open-conducting state 
for a prolonged time. Interestingly, some of the identified HVA calcium channels exhibited 
preferences to different tissues and different sensitivity to DHP and other toxin antagonists, 
which led to the identification and classification of diverse HVA channels.
DHP-sensitive channels were found to be present in various cells and exhibited a long-lasting 
activation length and hence are called the DHP channel or the L-type calcium channel (LTCC) 
[5, 6]. ω-CTX-sensitive calcium channels were pronounced for their roles in the nervous sys-
tem and are thus classified as N-type (non-L or neuronal) channels. ω-AGA-sensitive chan-
nels were initially found in the Purkinje cells of the cerebellum and are, therefore, named 
as P-type channels. Another close homolog of the P-type channel produced by alternative 
splicing of the CACNA1A gene was found and is referred to as the Q-type calcium channel. 
In addition to these three types of HVA, some calcium-conducting channels were found to be 
insensitive to any of these antagonists and have been classified as R-type (resistant) channels 
(Table 1).
Only one type of calcium channel has been reported among the LVA channels, namely, the 
transient-opening calcium channel (also called T-type channel). The T-type channels are 
similar to L-type channels in their diverse expression and antagonist resistant properties. 
However, small single-channel conductance and ability to be activated at lower membrane 
potentials make them distinct from the L-type channels.
The prevalence of N-, P/Q-, and R-channels in neurons, and L- and T-channels in broad cel-
lular types, shows the distinctive functional roles of the calcium channels. Besides their role 
in the characterization of the homologous channels, the calcium channel antagonists remain 
promising for their ability to specifically-modulate the different types of channels [10]. The 
varied sensitivities of the HVA and LVA channels to different antagonists show the potential 
for engineering these antagonists to selectively-alter the calcium conduction in different cells 
for various functions.
Type Antagonists sensitivity Ref
1,4-DHP Phenylalkylamine Benzothiazepine ω-CTX ω-AGA
CaV1 L-type Blocks Blocks Blocks Resistant Resistant [7]
CaV2.1P/Q-type Resistant Resistant Resistant Resistant Blocks [8]
CaV2.2 N-type Resistant Resistant Resistant Blocks Resistant [9]
CaV2.3 R-type Resistant Resistant Resistant Resistant Resistant [9]
Table 1. Blocker sensitivities of different HVA channels.
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Ten mammalian VGCCs have been identified, of which the L-type calcium channel includes 
four members, CaV1.1-CaV1.4, the P-/Q-type includes CaV2.1, the N-type includes CaV2.2, 
the R-type includes CaV2.3, and the T-type includes three members, CaV3.1–3.3. Their 
sequence similarity and evolutional relationship are shown in Figure 1. The following sec-
tions of the chapter will focus on comprehending the structure, and function of the LTCCs 
and their implications in drug discovery applications.
1.2. Distribution of LTCCs
The distribution of LTCCs varies widely across its’ members as their functions vary in dif-
ferent excitable cells [9]. Transcripts for all L-type channel isoforms have been detected in 
lymphocytes for endocrine functions [11]. Among the four LTCCs types, CaV1.1 is mainly 
distributed in skeletal muscle and plays a role in muscle contraction. It is co-expressed with 
ryanodine receptors (RYRs) in GABAergic neurons, which produces gamma-aminobutyric 
acid (GABA) [12]. CaV1.2 and CaV1.3 show a highly overlapping expression pattern in many 
tissues and are mostly present in same cell types, such as in adrenal chromaffin cells, cardiac 
and neuronal cells [13]. CaV1.2 and CaV1.3 are predominantly located post-synaptically on 
the cell soma and in the spine and shaft of dendrites in the neurons [14]. CaV1.2 and CaV1.3 
are also expressed in the sinoatrial node (SAN) and atrial cardiomyocytes and play a role in 
cardiac pacemaker activity [15]. In cardiomyocytes, CaV1.2 is mainly involved in the excita-
tion-contraction coupling. CaV1.3 are found in the pancreas and kidney, where it correlates 
with endocrine secretion, and in the cochlea to regulate the auditory transduction (Figure 1). 
CaV1.4 is primarily expressed in the retinal cells and helps in normal visual functions [16].
When the LTCCs detect the electrical signal on the cell membrane, they transform these signals into 
other physiological activities, such as contraction of the muscle, secretion of hormones, and regulation 
of genes [18, 19]. These processes can generally be summarized as excitation-contraction [18], 
excitation-secretion [19], and excitation-transcription coupling [12], respectively.
Figure 1. Phylogenetic tree showing the evolutionary relationship among the members of the VGCCs [2, 17]. And, the 
major distribution of the four LTCC isoforms in human tissues [12, 13, 18]. The tree was constructed using the Clustal 
omega. The scale in the figure shows the percentage of sequence identity in the CaVα
1
 subunit of different channels.
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2. Sequence-structure organization of L-type calcium channels
2.1. LTCC: domain organization
The purified LTCCs contains five subunits, the principal or pore-forming subunit, α
1
 
(170 kDa) and different auxiliary subunits, α2 (150 kDa), β (50–78 kDa), δ (17–25 kDa), and γ (32 kDa). The auxiliary subunits are non-covalently linked to the α
1
 subunit for modulat-
ing the biophysical properties and trafficking of the α
1
 subunit onto the membrane [20]. The 
α
1
 subunit corresponds to the pore-forming segment of LTCC to allow the passage of Ca2+ 
ions and is composed of approximately 2000 amino acids (AAs). The other components serve 
as auxiliary subunits and modify the function of the channel. For example, the β subunit 
and α2δ-subunit accelerate the activation and deactivation kinetics of the channel and signifi-cantly increases the maximal-conductance of ionic current [21]. The β subunit, which lacks the 
membrane-spanning region, is localized on the intracellular region of the channel. The α2 and δ subunit, although expressed by a single gene, are cleaved into two separate proteins dur-
ing post-translational modification resulting in a glycosylated extracellular α2 and a smaller membrane-spanning δ subunit that are held together (α2δ-subunit) by a disulfide bond. The transmembrane γ-subunit, another component of LTCCs has not been found in CaV1.2 and 
CaV1.3 of the cardiac cells [13]. The γ-subunit has not been extensively studied because of 
their relatively limited distribution and trivial functional roles. Figure 2 shows the arrange-
ment of CaV subunits.
2.2. LTCC: sequence and splice variants
The pore-forming α
1





), the CACNA1D (CaV1.3α
1
), the CACNA1F (CaV1.4α
1
), the CACNA1A (CaV2.1α
1
), the 
Figure 2. The LTCC complex. The pore-forming transmembrane α
1
-subunit, the intracellular β-subunit, the extracellular 
α2-subunit co-linked with the transmembrane δ-subunit, and the transmembrane γ-subunit are shown [3, 13].
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CACNA1B (CaV2.2α
1
), the CACNA1E (CaV2.3α
1
), the CACNA1G (CaV3.1α
1
), the CACNA1H 
(CaV3.2α
1
), and the CACNA1I (CaV3.3α
1
). The members of the three families (CaV1, CaV2, and 
CaV3) share high sequence similarity (above 80%). In particular, the CaV1 and CaV2 families 
have relatively high sequence similarity, when compared with that of the LVA CaV3 family. All 
these channels have large numbers of potential splice variants expressed in different tissues [12]. 
The splicing sites are mainly distributed in the structurally flexible regions, such as N-terminal, 
C-terminal, and linkers between the transmembrane domains. They contribute to regulation of 
genes, gaining diversity in proteins, and in fine-tuning the physiological functions of the channel.
2.3. Domain organization
The LTCC polypeptide forms a heterotetramer and includes the pore-forming transmembrane α
1
-
subunit, the intracellular β subunit, and an extracellular α2δ subunit. Most of the pharmacological and gating properties of LTCCs are accomplished by their α
1
-subunits. The structural topology 
of the α
1
-subunits is highly conserved among the members of the LTCCs and is made up of the 
cytoplasmic N- and C-terminal domains and four intervening transmembrane domains (DI-DIV). 
Each transmembrane domain is composed of six transmembrane α-helices (S1–S6), where S1–S4 
helices are known as the voltage sensing domain (VSD), and S5–S6 forms the pore domain [22]. 
VSD detects the changes in the membrane potential and PD helps in the selective passage of 
calcium ions through the channel pore. The S4 helix of the VSD encompasses several conserved 
positively charged residues, whereas, the S1–S3 helices are dominated by negatively charged 
amino acids. When the membrane is depolarized, the movement of the S4 helices is transmitted to 
the cytoplasmic ends of the S5 and S6 helices, through the S4–S5 linkers, resulting in the opening 
of the activation gate formed by the S6 helices on the inner side of the channel [3, 13].
The membrane-associated P-loop in each domain between the two helices, S5 and S6, form the 
selective filter of the channel. The selectivity of calcium channels relies on the P-loops domains 
and their calcium ion binding sites. The selectivity filter of VGCC includes conserved gluta-
mate residues (E–E–E–E) in the P-loop region [5]. Their side chains can restrain Ca2+ at the 
right coordination and let Ca2+ enter into the pore region. The recent research identified three 
aspartic acid residues along the selectivity filter from extracellular to intracellular. Amino acid 
substitution and crystallization, has helped in locating the three binding sites for the Ca2+ ions 
[5]. Although the bacterial calcium channel is different from the mammalian LTCCs in their 
amino acid sequence and structural features, the structure of CavAb has provided valuable 
insights into calcium ion selectivity conferred by the selectivity filter.
The N-terminus and C-terminus region of LTCC are both located in the cytosolic space. 
Although the major sequence of the N-terminus is composed of random loops, it also 
includes a calmodulin interaction domain, known as N-terminal spatial Ca2+ transforming 
elements (NSCaTE) [23]. The length of the C-terminus is much longer than N-terminus and 
contains several binding sites for various proteins that modulate the LTCCs activity (shown 
in Figure 3). Proteolytic cleavage of the C-terminal domain generates two fragments, the 
proximal C-terminal regulatory domain (PCRD) and the distal C-terminal regulatory domain 
(DCRD). The upstream sequence of the cleaved site contains the PCRD, IQ domain, pre-IQ 
domain, and the EF-hand motif. This region is important for Ca2+/CaM binding and regulation. 
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The downstream sequence from the cleavage site includes the A-kinase-anchoring-protein 
(AKAP) binding domain (ABD) and DCRD [3]. When the DCRD is proteolytically cleaved, 
the cleaved fragment can remain non-covalently bound to the PCRD, thus allowing the two 
regions of the C-terminal domain to interact with each other and perform the auto-inhibitory 
function for the LTCCs [24]. The DCRD serves as an effective auto-inhibitory domain for the 
LTCCs or as a transcriptional modular when it enters the nucleus [24]. The ABD of the distal 
C-terminus plays a vital role in PKA-induced phosphorylation of the DCRD. The AKAP binds 
with the ABD and helps PKA identify the phosphorylation sites in the cleaved fragment. The 
phosphorylation shuts down the auto-inhibition of LTCC and facilitates the Ca2+ influx [13].
Coexpression and co-assembly of CaVβ and CaVα2δ subunits with CaVα1 have a significant role in LTCCs trafficking [25]. The CaVβ subunit, which belongs to the membrane-associated 
guanylate kinase (MAGUK) protein family is composed of three domains similar to that of the 
MAGUK family, except for the missing PDZ in the N-terminus. The two conserved structural 
domains of the CaVβ, the SH3 and the guanylate-kinase (GuK) like domain are linked together 
by a HOOK domain. The HOOK domain of the CaVβ isoforms has variable lengths and share 
a relatively low overall amino acid identity and plays an important role in the CaVβ interaction 
with other proteins [26]. Similar to the DCTD, the HOOK domain possesses sites for phosphory-
lation and alters the conduction state of LTCCs. The CaVβ subunit interacts with the 18-residue 
long DI-II linker (or the alpha interaction domain (AID)) of the α
1
 subunit. The α-binding pocket 
(ABP), a hydrophobic groove formed by the surrounding α-helixes, in the GuK domain of the 
CaVβ subunit interacts with the AID [27]. The high-affinity association between AID and ABP 
markedly influences the cell surface expression of functional channels [26].
Figure 3. The secondary structure topology of the α
1
-subunit of LTCCs. The N-terminal domain is followed by four 
homologous transmembrane domains and the C-terminal domain. Each of the transmembrane domains is made of six 
helices and a membrane associated P-loop. The orange, purple, red, and gray dots indicate the location of NSCaTE, 
PCRD, AKAP binding domain, and DCRD, respectively [3, 22]. The linker of DI and DII, colored in yellow, is the alpha-
binding domain (ABD). The sequence from C1 to C2 and from C3 to C4 shows the two EF-hand motifs. Sequence from 
the end of C4 to the end of C6 colored in light blue is pre-IQ and IQ domain. The cleavage site is located in the sequence 
between DCRD and PCRD. The secondary structure is based on the PDBsum database.
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Another important co-expressed protein component of the LTCC complex is the CaVα2δ sub-unit. The α2δ subunit remains to be a promising target for the treatment of neuropathic pain and mutations that affect the function of CaVα2δ-1 were found to cause cardiac dysfunctions 
[25]. The CaVα2δ subunit is a disulfide-linked polypeptide that interacts with the α1 subunit on the extracellular space through its’ α2 segment, while the δ segment serves as an anchor fix-ing the subunit to the membrane. The CaVα2δ contains a similar domain arrangement to vari-ous plasma proteins, which includes Von Willebrand factor type-A (VWFA) and the calcium 
channel and chemotaxis (CACHE) domain [28]. The VWFA domain found in CaVα2 promotes the trafficking of the α
1
 subunit to the membrane and acts as a receptor for the extracellular 
ligands, such as thrombospondins. This VWFA domain also contains a metal ion-dependent 
adhesion site (MIDAS), which allows precise coordination of the VWFA domain with bound 
protein ligand [29]. Mutation of this site can result in the loss of CaVα2δ subunits’ regulatory function to the CaV1.2, CaV2.1, and CaV2.2. Nevertheless, the CaVα2δ subunit can still help in trafficking the CaVα
1
 subunit to the cytoplasmic membrane. The CACHE domain is located 
at the downstream sequence of VWFA domain in the extracellular side. This domain is known 
to have a possible role in small-molecule recognition [21, 28].
3. Three-dimensional structures of LTCCs
Elucidating the three-dimensional (3D) structure of membrane proteins is challenging due 
to their intricate environmental conditions. Until now, there are no complete 3D structures 
available for the human voltage-gated calcium channels. The 3D structures of two specific 
regions of VGCCs in complex with their auxiliary subunits have been resolved, the AID-
CaVβ complex and the IQ domain-calmodulin (Ca2+/CaM) complex. Recently, the structure 
of Arcobacter butzleri calcium channel (CaVAb) and the mammalian CaV1.1 were determined 
using crystallography and cryo-electron microscopy (EM) techniques, respectively. These 
structures have provided significant insights on the ion selectivity and drug-binding sites in 
the calcium channels.
3.1. The AID-CaVβ complex
The crystal structures of three isoforms of CaVβ have been resolved in complex with the AID 
(i.e., short polypeptides from the DI-II linker of CaVα
1
) from different species [30]. The 2.2 Å 
resolution structure of rabbit CaVβ2 isoform was crystallized in complex with an 18-residue long polypeptide, corresponding to the AID of CaV1.1α
1
 (PDB ID: 1T3L). The core region 
of rat CaV1.2 β3 isoform was crystallized (PDB ID: 1VYV) with a polypeptide (49 AAs) at 2.6 Å resolution. Chen et al. crystallized the single structure of CaVβ
4
 isoform at 3 Å resolu-
tion (PDB ID: 1VYU) [30]. Their core structures, which includes the SH3 and GuK domains, 
exhibit high similarity. A chimeric complex of rat CaVβ2 isoform and first 16 residues of human CaV1.2 AID region was crystallized at 1.97 Å resolution (PDB ID: 1T0J) [26]. Mutation 
analysis showed that three CaV1.2 AID residues, Tyr447, Trp440, and Ile441 are important for 
the interaction between the CaVβ subunit and the AID [26, 30].
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In 2012, a 2.0 Å resolution crystal complex of rabbit CaV1.2 DI-DII linker and CaVβ2 iso-
form was determined [27]. Not until recently, the 3D structure of the last isoform of CaVβ 
subunit, the CaVβ
1
, has been identified in a complex with the complete cryo-EM model of 
rabbit CaV1.1. The mechanism that CaVβ regulates CaVα
1
 is achieved through the transmit-
ted motions of DI-S6. Before association with CaVβ, AID is in a coil-type structure. The CaVβ 
acts as a chaperone and helps AID undergo a coil to helix transition during the binding [31]. 
The α-helix of AID propagates the upstream sequence of DI-S6. They form a rigid connection 
between the GuK domain of the CaVβ and the channel pore, and mechanically transduce 
their binding to channel gating states [30]. The N-terminus of the CaVβ is anchored to the 
membrane, which restricts the motion and orientation of the CaVβ binding to the AID and 
connecting the DI-S6 segment. These coupled motions help CaVβ effectively regulate the gat-
ing properties of calcium channel.
3.2. The IQ domain-calmodulin (CaM) complex
Calmodulin (CaM) is a small and conserved calcium-binding messenger protein that plays an 
essential role in all the HVA channels. In the case of LTCCs, binding with Ca2+/CaM is known 
to pronounce calcium-dependent inhibition of the channel current. Calmodulin, being local-
ized in the cytosolic region, detects the changes in the levels of intracellular Ca2+ and modu-
lates the interaction of LTCCs with other proteins. Four EF-hand motifs distributed equally on 
the N- and C-terminus of the CaM works as the calcium ion sensor. Each of EF-hand motifs is 
composed of two alpha helices and is connected by a flexible loop with the Ca2+ binding site 
located in the middle. The Ca2+/CaM has a higher binding affinity to LTCC and therefore asso-
ciates with the LTCC complex even at low cytoplasmic Ca2+ concentrations. The IQ domain 
and the pre-IQ domain, upstream sequence of the IQ domain, serve as the binding site for the 
calmodulin. CaM is known to play a regulatory role in the calcium-dependent inactivation of 
LTCCs. However, the trafficking function of Ca2+/CaM remains controversial, due to inconsis-
tent results in different expression systems [32]. In hippocampal neurons, CaV1.2 trafficking to 
the distal dendrites is accelerated by the presence of Ca2+/CaM, and not by the apo-CaM [33].
From 2005 to 2012, several structures containing a short polypeptide from CaV1.1 or CaV1.2 
and calcium-bound calmodulin (Ca2+/CaM) were determined. In 2005, three structures of the 
CaV1.2 IQ domain bound to the hydrophobic pocket of the Ca2+/CaM protein were resolved 
[34, 35]. In those complexes, Ca2+/CaM exists in a 2:1 ratio with the IQ domain [36]. IQ domain 
engages itself in the hydrophobic pockets, present in the N-terminal and C-terminal Ca2+/CaM 
lobes, through sets of conserved ‘aromatic anchors’. In the CaV1.2, three residues (Tyr1627, 
Phe1628, and Phe1631) downstream of IQ domain bind the hydrophobic Ca2+/C lobe pockets. 
The three upstream residues (Phe1618, Tyr1619, and Phe1622) bind the Ca2+/N lobe pockets 
[34]. The lengths of CaV1.2α
1
 IQ domains vary among the resolved structures. For example, 
the 3D structures of human IQ domain have been resolved with 37 residues (PDB ID: 2BE6), 
and 21 residues (PDB ID: 2F3Z, PDB ID: 2VAY) [37], and 21 residues from Cavia porcellus (PDB 
ID: 2F3Y). In 2009, Fallon et al. resolved the extended structure of IQ domain to include the 
pre-IQ domain, which comprised of 77 residues from human CaV1.2 C-terminus (PDB ID: 
3G43) [38]. In 2010, the structure of PreIQ and IQ domain from human CaV1.2 containing 78 
residues (PDB ID: 3OXQ) was crystallized in complex with Ca2+/CaM at 2.55 Å resolution [36]. 
In 2012, Liu and Vogel reported a novel-binding motif (NSCaTE) from N-terminus of CaV1.2 
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and CaV1.3 to have a higher affinity for binding Ca2+/CaM when compared to that of the bind-
ing region in C-terminus [23]. Using NMR, they reported the 3D structure of a 24-residue long 
NSCaTE motif in complex with the Ca2+/CaM (PDB ID: 2LQC). Until now, the Ca2+/CaM com-
plex structure has only been resolved with CaV1.1 and CaV1.2 of the LTCCs. Although CaV1.4 
binds to Ca2+/CaM, their interaction has not been reported to have any functional regulation.
3.3. The structure of bacterial CaV channel
In 2014, the first structure of a bacterial calcium channel (CaVAb) was resolved by perform-
ing specific mutations on the Arcobacter butzleri sodium channel (NaVAb) [5]. The quaternary 
structure of CaVAb is a symmetrical homo-tetramer, which is similar to its NaVAb prototype. 
Four identical domains assemble to form the main structure of the channel, with each of the 
domain (containing 237 residues) encompassing six transmembrane helices. The topological 
features of the transmembrane domain of the CaVAb are similar to that of the LTCC. Tang 
et al. performed several mutations to elucidate the structural basis of Ca2+ selectivity and 
reported the crystal structures of 13 variants that conferred different mutations in NaVAb.
Each monomer is composed of a voltage-sensing domain (S1–S4) and a pore-forming domain 
(S5–S6). Four positively charged arginines in the voltage-sensing domain detect the changes in 
the membrane potential. The voltage-sensor movements are transmitted to the pore-forming 
domain through a cytoplasmic linker that connects the S4 and S5 helices. Three negatively 
charged aspartate residues at the selectivity filter (Asp177, Asp178, and Asp181) were found 
to be essential for binding the Ca2+ ion and render selectivity to the channel. The paper 
revealed that the ion-selective mechanism is based on three Ca2+ binding sites, site-1 (Asp178), 
site-2 (Asp177, Leu176), and site-3 (Thr175). A single substitution at site-177, from Glu to Asp, 
enhanced the calcium selectivity by 1000 times over sodium, which was sufficient to convert 
the sodium channel to calcium channel. Although 181D is not directly involved in Ca2+ coor-
dination and lies outside of the ion-conducting pore, it generates an electronegative environ-
ment to attract the extracellular cations. Binding of one Ca2+ blocks the pore and prevents the 
entry of the monovalent cations. The entry of second Ca2+ induces electrostatic repulsion on 
the first Ca2+, thereby forcing it to flux into the cytoplasm. Thus, the extracellular calcium ions 
fluently permeate into the intracellular side in response to the concentration gradient [5].
3.4. Structure of CaV1.1
In 2015, Wu et al. reported the complete structure of the mammalian CaV1.1 complex at 4.2 Å 
resolution using the cryo-EM technique [39]. Three auxiliary subunits were isolated from 
the rabbit skeletal muscle, the pore-forming α
1
-subunit, the extracellular α2δ-subunit, and the transmembrane γ-subunit. The fourth auxiliary subunit was included in the complex by 
docking the crystal structure of rat CaVβ2 (PDB ID: 1T0J) on the AID of CaV1.1α1 subunit. Following this complex, two rabbit CaV1.1 complexes at resolution 3.9 Å (PDB ID: 5GJW) and 
3.6 Å (PDB ID: 5GJV) were reported [40]. This CaV1.1 construct included 1873 amino acid resi-
dues. While the 3D coordinates of most parts of the CaV1.1 α
1
-subunit were resolved, some 
of the cytoplasmic (N-terminus: 1–31, DI–DII linker: 377–416, DII–DIII linker: 670–787, and 
C-terminus 1516–1873) and extracellular segments (DI S3–S4: 140–160, DIII S3–S4: 886–891, 
and DIV S3–S4: 1206–1228) were found to be missing (Figure 4).
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The rabbit CaV1.1 is composed of four inter-connected homologous domains, each of which 
includes the voltage-sensing and pore-forming domain. The S4 helix of the VSD is composed 
of six charged residues when compared to four residues in human CaVs [41]. Remarkably, the 
asymmetric pore-region of CaV1.1 is formed by the four S5, and S6 bundles and the tightly 
packed inner gate showcased a closed conformation and inactivated conduction-state of the 
CaV1.1 channel. The auxiliary CaVα2 subunit included four tandem cache domains and one VWA domain. The cysteine residues, Cys1074 in CaVδ and Cys406 in CaVα2 formed a disul-fide bond at the binding region between VWA domain and CaVδ. In the VWA domain, the 
MIDAS residues (Ser263, Ser265, Asp261, Thr333, and Asp365) and CaVα
1
 DI S1–S2 residue 
(Asp78) are bound to a calcium ion. Both the previous and latest 3D structures identified for 
the CaVγ subunit included four transmembrane α-helices, however, in this CaV1.1 struc-
ture, additional extracellular β-sheets have been resolved together with the regions of the 
two termini. The second and third transmembrane-helices in CaVγ and DIV S3-S4 in CaVα
1
 
are directly involved in interactions through hydrophobic forces. The Cryo-EM structure of 
the rabbit CaV1.1, have thus brought novel insights on the multi-domain structure of VGCC, 
especially the association of CaV with the auxiliary proteins.
3.5. Computational modeling
Computational modeling and simulation remain to be a promising technique to reveal funda-
mental biological mechanisms, biomolecular interactions and predicting the effects of modu-
lators. In CaV, modeling-based studies were previously performed to understand how LTCC 
blockers bind the calcium channel [42–44]. Tikhonov and Zhorov generated homology models of 
the open- and closed-state conformation of the pore-forming domains of CaV1.2 using the crystal 
structure of the KvAP and KCSA channels as the template [45]. The generated models were used 
to dock three types of LTCC blockers, benzothiazepine, phenylalkylamine, and dihydropyridine. 
The docking analysis showed that the all the three ligands bind near the S5–S6 helices of domain 
III and IV and the CaV residues, tyrosine in S6-DIII, tyrosine in S6-DIV, and glutamine in S5-DIII, 
are important for binding these ligands close to the pore domain of the channel. Since no exper-
imentally-resolved structure of small molecule-CaV was available, in silico the docking analysis 
performed in this study provided useful insights for understanding ligand-binding in CaV.
Adiban et al. used the structure of the CaVAb (PDB ID: 4MVQ) to model the selectivity filter 
of the CaV with defined charges. They performed molecular dynamics (MD) simulation to 
calculate the potential of mean force and showed that the affinity for Ca2+ in site-2 (Asp177, 
Leu176) is higher than that within the two other sites, site-1 (Asp178) and site-3 (Thr175). 
Their study also showed that, in the absence of calcium ions, the CaVAb could allow the pas-
sage of Na+ ions, but not Cl− ions [46]. This study using the structure of CaVAb, was helpful in 
understanding the structure–function relationships of the calcium channel.
Figure 4. The missing residues in the rabbit CaV1.1-α
1
 structure (PDB ID: 5GJV) shaded in gray.
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All of the computational models built for CaV until now were based on templates with low 
sequence identity (<30%). Studying molecular systems built with low-identity templates 
is quite challenging since the accuracy of the model is highly dependent on the similarity 
between the template and the target protein [47]. While the oligomeric structures of bacte-
rial homologs are useful for modeling the transmembrane domains (TMDs), building the 
large intracellular domains that connect the TMDs using these structures is not feasible. With 
the availability of the CaV1.1 complex and other structural data, obtaining better quality 
homology-based models for the human CaV channels, especially the LTCCs, is now possible. 
Nevertheless, sophisticated methods and high-performance computing would be needed for 
modeling the multi-domain architecture of the human CaVs. Building these models can be 
helpful in understanding the structure-function-dynamic properties, the Ca2+ influx mecha-
nisms and effects of small molecules on these channels [48, 49].
4. Activation mechanisms of LTCCs
LTCC, being a voltage-gated ion channel, remains mostly sensitive to the changes in the mem-
brane potential and the VSD (S1–S4 helices) of the LTCCs play a crucial role in sensing the 
voltage changes across the membrane. In addition to the voltage-dependent gating mecha-
nisms, the channel’s conductivity also depends on the intracellular Ca2+ concentration, and 
thus is modulated by both self-regulatory and extrinsic mechanisms.
4.1. Voltage-dependent activation/inactivation mechanism
The cardiac action potential is a classic example of the voltage-dependent mechanism. During 
the action potential, the ions channels undergo several conformational transitions and regu-
late the exchange of ions across the membrane. When the intracellular gates of the channel 
are open, the channel is referred to be conducting. The smooth passage of ions through the 
open-pore of the channel generates the electrical current across the membrane. When the 
membrane depolarizes, the inactivation gates of the channel are closed, while the intracellular 
gates are still open to allow the decay of current levels. Inactivation is a way to decrease the 
availability of the open-state of the channel at more depolarized membrane potentials [50]. 
The closed state of the channel corresponds to the closed intracellular gates, which hinders 
the ion passage, and results in a non-conducting state.
The action potential can be divided into five phases (Phase 0–4, shown in Figure 5) and the con-
certed activities of various ion channels in the heart help in maintaining the cardiac rhythm. 
In simple terms, at phase 0, the membrane is initially at the resting potential (−90 mV), where 
the LTCCs are in a closed-state (no Ca2+ ion passage). When depolarization occurs, and the 
membrane potential reaches a threshold voltage of −70 mV, the inward sodium ion (Na+) 
channels are activated allowing the flow of the INa current. This current flow further increases 
the membrane potential to a more positive value and reaches a peak, when the activation 
of LTCCs are initiated, and the sodium channels are inactivated. During phase 1, early and 
rapid repolarization occurs by the brief activation of K+ channels and the LTCCs remain in 
a pre-open state. After phase 1, the opening of the LTCCs (open/activated state) slows the 
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repolarization down. This phase of the cardiac action potential, the phase 2, is called a plateau 
phase and is maintained by the balancing act of the Ca2+ and K+ ions (shown in Figure 5). 
This Ca2+ influx that occur during phase 2 initiates the contractile function of the cardiac cells. 
Close to the end of phase 2, when more Ca2+ ions are released an auto-inhibitory signal is trig-
gered resulting in a non-conducting state or closed state of the calcium channel.
During phase 3, the cell tries to return to the resting state by the gradual inactivation of the 
calcium channels (inactivated state) and continued efflux of K+ ions [51]. At the end of phase 
3 inward rectifying K+ channels are activated to reset the membrane potential to the rest-
ing state. The last phase of the action potential, in phase 4, the membrane returns to resting 
potential (−90 mV), which allows the LTCCs to transit from the inactivated state to the closed 
state for the next cycle of events. This resting potential of the membrane is maintained by the 
continued leak of the K+ ions.
Given the tissue-specific localization of the members of LTCCs and their different functional 
roles relevant to the region of expression, these channels also have different activation thresh-
old and kinetics. For example, the CaV1.1 and CaV1.2 require a depolarized threshold of +7 
and −30 mV, for their activation [2, 52]. The CaV1.3 and CaV1.4 do not require a depolarized 
threshold as strong as CaV1.1 and CaV1.2, to be activated and have relatively low activation 
thresholds of about −55 and −40 mV (Figure 5), respectively. Similarly, CaV1.3 channels are 
known to activate with fast kinetics when compared to that of the CaV1.1 [53]. Although 
CaV1.3 is closely related to CaV1.2, it seems to share more similar properties with CaV1.4, 
including rapid activation kinetics, low activation threshold, and lower sensitivity to 1,4-
DHPs [53].
4.2. Calcium-dependent activation/inactivation mechanism
The calcium-dependent channel regulation process requires the participation of multiple seg-
ments, such as the β-subunit [57], Ca2+/CaM [58], CaMKII [59], N-terminal and C-terminal 
regions of the LTCC CaVα
1
. Calcium-dependent inactivation serves as the autoinhibitory 
control for the LTCCs to control the levels of intracellular calcium. It is mediated by the inter-
actions between the Ca2+/CaM and CaV pre-IQ/IQ domains. Disruption to this interaction has 
Figure 5. (A) Cardiac action potential (left) [54]. (B) Activities of three types cation channels during phase 2. The inward 
sodium and calcium current decays with time; the outward potassium current is activated allowing the cell to move to 
resting state [55]. (C) CaV1.2 and CaV1.3 voltage potential amplitude. Plot re-generated from Xu and Lipscombe data [56].
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been known to attenuate the calcium-dependent inactivation process. At the resting potential, 
apo-CaM associates with the alpha-subunit of the channel. When Ca2+ ions bind the CaM, the 
fully charged CaM with four Ca2+ ions allow the two polarized lobes of the CaM, the Ca2+/N 
lobe, and the Ca2+/C lobe, to envelope the alpha-binding helix. Specific interactions of two 
lobes with the IQ domain initiate different calcium-dependent regulations. For example, in 
CaV1.2 and CaV1.3, CDI is caused by the interaction between the IQ domain and the Ca2+/C-
lobe, while CDF is facilitated by the interaction of the Ca2+/N-lobe and the IQ domain [24, 35]. 
In contrary, the IQ domain interactions with the Ca2+/N-lobe and the Ca2+/C-lobe in the CaV2.1 
channel, lead to CDF and CDI, respectively [60, 61].
Ferreira et al. [62] reported that calcium-dependent mechanisms could speed up the inactiva-
tion process. They used barium in the place of calcium ion and found that the channels undergo 
rapid activation and slow inactivation due to the lack of intracellular calcium. Their result 
showed that voltage-dependent mechanisms alone in the absence of calcium-dependent mech-
anisms would lead to slower inactivation [24, 53]. While CaM promotes calcium-dependent 
inactivation, the Ca2+/calmodulin-dependent protein kinase II (CaMKII) counteracts the above 
process and helps in the re-activation of the channel in a calcium-dependent way. CaMKII 
phosphorylates the CaVβ subunit and the C-terminus of CaVα
1
 at their specific phosphoryla-
tion sites, resulting in the disruption of CaM-CaV channel interactions. Increase in the intracel-
lular calcium ion level activates the CaMKII and reduces the effects of CDI [12, 59]. CaMKII 
enables the channel gates to be frequently left in the open state for a long time thus, prolonging 
the plateau phase of the action potential at high frequency.
5. L-type calcium channels modulators
The LTCCs are considered as an important target for the treatment of various diseases [9, 
63–66]. CaV1.1, the major isoform of the skeletal LTCCs is reported to correlate with hypo-
kalemic periodic paralysis, which is characterized by muscular weakness or paralysis [63]. 
CaV1.2 and CaV1.3, being more expressed in the heart and the brain, their dysfunction results 
in severe disease states, such as Timothy’s syndrome, cardiac arrhythmia [6], bipolar disor-
der, and autism [64, 65]. Any abnormality in the cardiac LTCCs leads to long-QT syndrome 
(LQTS), where the QT interval of the cardiac action potential is prolonged, a condition that 
causes heart arrhythmias or sudden cardiac death (SCD) [67]. The Timothy Syndrome (TS), 
is an extremely rare multisystem LQTS subtype, that is mainly caused by the dysfunctions of 
LTCC and Ca2+ handling proteins. As the only LTCC subtype in the retinal cells, mutations in 
the CaV1.4 gene are known to weaken the normal visual functions and cause night blindness. 
Modulating LTCCs, therefore, remains to be an important avenue for the treatment of several 
diseases.
5.1. Small molecule modulators
Fleckenstein showed that small organic molecules, like verapamil, specifically inhibited the 
Ca2+ current from LTCCs [66]. Since then, several small-molecule modulators of the LTCCs 
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have been identified. Most LTCC drugs can be grouped into one of these three groups, phe-
nylalkylamines, benzothiazepines, and dihydropyridines [9]. All LTCCs exhibit a similar 
pharmacological profile upon treatment with the drug, including the high- affinity frequency-
dependent block [9]. These three classes of drugs bind to three allosterically linked receptor 
sites on the LTCCs and block the inward calcium current [68]. Previous studies showed that 
these three classes of drugs bind at three distinct sites, however with overlapped binding 
domains [43, 69]. All three binding sites are close to the pore and are located within the S5 
and S6 helices of DIII and S6 helix of DIV [68]. Tikhonov and Zhorov choose the KvAP and 
KcsA crystal structure as the template to model the open state and the close state of CaV1.2, 
respectively. Based on this template, they investigated the binding mode of dihydropyridine  
[43] and benzothiazepine [42] and confirmed their binding in this region. However, the co-
crystallized structure of CaVAb-verapamil complex suggests that the verapamil-like phenyl-
alkylamines can bind within the pore of the channel [6].
5.1.1. DHPs and related drugs
The 1,4-dihydropyridine (1,4-DHP) is an effective and specific LTCCs blocker that is com-
monly used for the treatment of cardiovascular diseases, such as vasodilation, angina, and 
hypotension [45, 68]. DHP-derived drugs, such as amlodipine, clevidipine, and felodipine 
are also used for the treatment of cardiac diseases [7]. Nimodipine, another DHP-based drug, 
regulates the LTCCs distributed in neurons and helps in improving the outcomes of neuro-
logical treatments [7, 65]. Most DHP-based antagonists prefer binding to the inactivated states 
of the channel and stabilize them to block the Ca2+ influx. Since most 1,4-DHPs are lipophilic, 
they also tend to bind on the outer surface of the channel facing the lipid molecules and form 
interactions with the S6 of DIII and DIV [53]. Four DIII residues (Tyr1152, Ile1153, Ile1156, 
Met1161) and one DIV residue (Asn1472) were found to be important for binding DHP-based 
drugs. Amino acid substitutions on the residues mentioned above were found to cause more 
than a five-fold decrease in the binding affinity of these compounds. Also, substitutions in the 
DIII and DIV residues of CaV1.2 (Phe1158, Phe1159, Met1160, Tyr1463, Met1464, Ile1471) are 
known to cause the about two- to fivefold decreases in the binding affinity [69].
5.1.2. Phenylalkylamine and related drugs
Verapamil is the prototype phenylalkylamine and is the only drug currently available from 
this class for clinical use [9, 68]. It is widely used for the treatment of hypertension. The sig-
nificant differences in the binding affinities of phenylalkylamine towards the different con-
duction states of the channel show that these drugs, similar to DHPs, most likely bind to 
the inactivated state of LTCCs [7, 66, 68]. It has been shown that phenylalkylamine binding 
causes the channel to hardly recover from the repolarization [68, 69]. It is known from the 
co-crystallized structure of CaVAb that phenylalkylamine binds in the central cavity of the 
pore on the intracellular side of the selectivity filter [6]. Upon binding, the drug results in 
the physical blockade of the channel and thus, preventing the passage of calcium ions. The 
Br-verapamil interacts with the surrounding residues, including Met174, Leu176, and two 
Thr206, from the S6 helices of each domain.
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5.1.3. Benzothiazepine and related drugs
Diltiazem, a clinically approved LTCC antagonist from the benzothiazepine class, is used for 
the treatment of arrhythmias. The diltiazem exhibits modest selectivity for LTCCs in vascular 
smooth muscle over cardiac muscle. Similar to the other two types, benzothiazepine tends 
to bind the inactivated state of LTCCs and share similar binding site as that of the 1,4-DHPs. 
Based on the photoaffinity labeling experiments, the binding sites of diltiazem was located 
within the S6 of DIII and DIV. Specific amino acid residues, Tyr1463, Ala1467, and Ile1470 that 
are present in the S6 helix of the DIV have been identified to be important for benzothiazepine 
blocking [68].
In addition to the α
1
-subunit, the α2δ-subunit of LTCCs are also considered as a promising 
target for regulating the channel functions [70]. Pregabalin and gabapentin are α2δ-subunit targeting small molecules that are being used for the treatment of chronic neuropathic pain 
[9, 29]. It has been shown that these two molecules are sensitive only to CaVα2δ1 and CaVα2δ2 and not to other isoforms of CaVα2δ [21]. These drugs work through the association of CaVα2δ and CaVα
1
 and inhibit the calcium channel activity in two ways. First, the association of 
CaVα2δ and CaVα1 increases the current amplitude. Binding with ligands inhibits this effect. Second, these drugs modify the channel activation by affecting the channel surface trafficking 
[71]. Interactions with ligands decrease the α2δ-subunit surface expression and LTCC traffick-ing, which in turn reduces the overall calcium inward currents [70]. Using alanine-scanning 
mutagenesis these drugs have been identified to bind to an arginine residue (Arg217) on the 
extracellular side of the channel. Due to their extracellular binding characteristics, these drugs 
are not required to enter the cell to bind their target, which makes them an attractive alterna-
tive therapy for the treatment of neurological diseases [7]. Table 2 summarizes the binding 
region, targeted disease, and chemical structure of LTCC targeting drugs.
5.2. Peptide modulators
Apart from the small molecular modulators, few natural toxin proteins have been known 
to specifically block the LTCCs. Two groups of toxins that selectively block the CaV2 sub-
family have been identified: the ω-conotoxin family of pore blockers and the functionally 
heterogeneous ω-agatoxin family of pore blockers [8]. Recently, Findeisen et al. reported a 
peptide-based inhibitor for the CaV. The CaVβ subunit exhibits a chaperone-like function 
and induces a helical conformation on the AID from its’ coiled structure, upon binding. The 
helix-conformation of AID has a higher binding affinity towards the CaVβ subunit [27, 72]. 
Based on this mechanism, Findeisen et al. [57] developed a stapled meta-xylyl (m-xylyl) AID, 
that is compatible to bind the CaVβ subunit. The stapled peptide, having a higher helix pro-
pensity had a higher chance to bind the CaVβ when compared to that of the native AID. This 
peptide inhibited the interaction between the AID and CaVβ (Kd CaV1.2-AID: 6.6 ± 2.0 nM, 
Kd AID-CEN: 5.2 ± 1.5 nM) and served as an antagonist for the calcium channel. The crystal 
structure of the stapled peptide in complex with the AID region of the human CaV1.2, and the 
rat CaVβ2 was resolved at 1.7 and 2.0 Å resolution, respectively (PDB ID: 5V2Q, 5V2P). Thus, peptide-based inhibitors are also of interest in modulating the CaV channel.




Voltage-gated calcium channels (VGCCs), which are responsible for the calcium flux in cells, 
play a key role in many physiological processes, including neurotransmission, cell cycle, 
muscular contraction, cardiac action potential, gene expression, and protein modulation. 
Drug Drug class Binding region Targeted disease 2D-structure
Amlodipine 1,4-Dihydropyridine CaVα1 IIIS5-S6, IIIS6, IVS6 Hypertension, chronic stable 
angina
Clevidipine 1,4-Dihydropyridine CaVα1 IIIS5-S6, IIIS6, IVS6 Hypertension
Felodipine 1,4-Dihydropyridine CaVα1 IIIS5-S6, IIIS6, IVS6 Hypertension
Isradipine 1,4-Dihydropyridine CaVα1 IIIS5-S6, IIIS6, IVS6 Hypertension
Nicardipine 1,4-Dihydropyridine CaVα1 IIIS5-S6, IIIS6, IVS6 Hypertension, chronic stable 
angina
Nifedipine 1,4-Dihydropyridine CaVα1 IIIS5-S6, IIIS6, IVS6 Hypertension, vasospastic 
angina, chronic stable angina
Nimodipine 1,4-Dihydropyridine CaVα1 IIIS5-S6, IIIS6, IVS6 Improve neurologic outcome
Nisoldipine 1,4-Dihydropyridine CaVα1 IIIS5-S6, IIIS6, IVS6 Hypertension
Diltiazem Benzothiazepine CaVα1 IIIS6, IVS6 Hypertension








CaVα2δ Epilepsy, neuropathic pain
Table 2. Common L-type calcium channel inhibitors. The list of drugs and the 2D structures are obtained from the 
Drugbank database.
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Their abnormal functions result in increased intracellular calcium levels and trigger serious 
pathological effects from cardiovascular and neuronal diseases to cancer. VGCCs are there-
fore considered as a significant target and development of isoform-specific modulators for 
VGCCs remain promising in pharmaceutical research.
The diverse expression patterns of the L-type and T-type channels show that these channels 
are pharmacologically important in several cancers, Parkinson’s disease, sensory diseases and 
cardiac diseases. The N-type channels, although present in different organs, is known for their 
activity in the nervous system and are considered as a target for pain and nervous disorders. On 
the other hand, the P/Q-type, which is preferably expressed in the neuronal cells, is attributed 
to neurological diseases, such as migraine, Alzheimer’s and ataxia. For several decades, non-
selective calcium channel blockers have been used for targeting the calcium channels for vari-
ous treatments. The FDA approval of ziconotide (N-type channel blocker) and the specificity 
of ω-agatoxin to P-/Q-type channels have attracted the development of more isoform-specific 
blockers [9]. Given the diversity in the roles and expression of calcium channels, specific target-
ing of these channels seems to be a promising strategy for therapeutic innovations.
7. Conclusion
In this chapter, we provide a comprehensive overview of the different types of VGCCs, 
especially the LTCCs, their sequence, structure, distribution, functional, and biophysical/bio-
chemical variations. Numerous studies have reported these key features, including the struc-
tural and functional properties of different CaV channels. For instance, the recent structures 
of CaVAb and the rabbit CaV1.1 paved the way for understanding the structure–function 
connections of ion-selectivity mechanism, self-regulation, and small-molecule interactions. 
However, till date, the complete structures of the human CaV isoforms have not been resolved, 
which remains to be a hurdle for understanding the intrinsic disease-related mechanisms 
of the channel. With the advent and application of various technologies, such as cryo-EM, 
NMR, crystallography, molecular modeling, and molecular dynamics, it could be possible 
to resolve the complete structure of the human isoforms. Having this structural information 
in-hand would help in understanding the structure–function relationships of these channels, 
and thereby in the development of isoform-specific calcium channel modulators.
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